<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC6439212/results/search/drug/results.xml">
  <result pre="(Pol/RT) was modeled and docked with the active compounds, including" exact="lamivudine" post="as standard. Docking of lamivudine indicated strong interaction with"/>
  <result pre="with the active compounds, including lamivudine as standard. Docking of" exact="lamivudine" post="indicated strong interaction with the modeled HBV Pol active-site"/>
  <result pre="with HBV Pol inhibitors, the nucleot(s)ide analogs (e.g., lamivudine, adepovir," exact="entecavir" post="etc.) leads to the emergence of drug-resistance in the"/>
  <result pre="Wu, 2016, Parvez et al., 2016). Compared to interferons or" exact="lamivudine" post="treatment, some plant products are reported with similar or"/>
  <result pre="naringenin were purchased (Sigma-Aldrich, Germany). The approved anti-HBV nucleoside analog," exact="lamivudine" post="(3TC; Sigma-Aldrich, Germany) served as standard (positive control). 2.2"/>
  <result pre="serum (Gibco, USA), 1x penicillin-streptomycin (Invitrogen, USA), and 1x sodium" exact="pyruvate" post="(HyClone Laboratories, USA) at 37 0C in a humidified"/>
  <result pre="grown over night. Compounds were first dissolved in 50 μl of" exact="dimethyl sulfoxide" post="(DMSO) following final preparation in culture media (1 mg/ml). Five"/>
  <result pre="10 μg/ml was chosen for all pure compounds in anti-HBV experiments." exact="Lamivudine" post="(2 μM) prepared in DMSO and RMPI, was included as"/>
  <result pre="for screening the binding modes of antiviral natural compounds, including" exact="lamivudine" post="(Fig. 1) in Autodock Vina and PyRx virtual screening"/>
  <result pre="HBsAg expressions relative to untreated control in HepG2.2.15 culture supernatants." exact="Lamivudine" post="(2 μM) was used as a reference anti–HBV drug. Values"/>
  <result pre="to untreated control in HepG2.2.15 culture supernatants at day 5." exact="Lamivudine" post="was used as a reference anti–HBV drug. Values (Y–axis):"/>
  <result pre="- MET250 Hydrophobic (Alkyl) 4.81 *Standard/positive control. 3.7.1 Lamivudine-Pol interaction" exact="Lamivudine" post="(Fig. 7A) is the first generation nucleot(s)ide-based anti-retroviral drug"/>
  <result pre="used in the treatment of HIV/AIDS and CHB. Docking of" exact="lamivudine" post="(as control) to HBV Pol indicated that it was"/>
  <result pre="and two carbon-hydrogen bonds with Ala181. Other residues that surrounded" exact="lamivudine" post="were Gln182 and Ser185 as well as Tyr203 and"/>
  <result pre="Embelin Benzoquinone −6.0 2.5 × 104 Menisdaurin Cyanoglycoside −6.5 8.9 × 104 Baccatin III" exact="Taxol" post="−7.0 1.4 × 105 *Standard/positive control. ^Binding free energy. ^^Binding affinity."/>
  <result pre="delineate the binding mechanism of the anti-HBV active compounds and" exact="lamivudine" post="(ligands) to the modeled HBV Pol (receptor), we performed"/>
  <result pre="modeled HBV Pol (receptor), we performed molecular docking. Docking of" exact="lamivudine" post="indicated that it strongly interacted with the active site"/>
  <result pre="Pol ‘YMDD’ motif residues, Tyr203 and Met204 were among the" exact="lamivudine" post="surrounding amino acids. Quercetin, a widely distributed plant flavonol"/>
  <result pre="was lesser as compared to its reported higher activity to" exact="lamivudine" post="(Yi et al., 2015). In the docking analysis, menisdaurin-HBV"/>
  <result pre="in-vitro and molecular docking analysisJ. Biomol. Struct. Dyn.2017 RehmanM.T.AhmedS.KhanA.U.Interaction of" exact="meropenem" post="with 'N' and 'B' isoforms of human serum albumin:"/>
  <result pre="docking studyJ. Biomol. Struc. Dyn.34201618491864 RehmanM.T.ShamsiH.KhanA.U.Insight into the binding of" exact="Imipenem" post="to Human Serum Albumin by spectroscopic and computational approachesMol."/>
 </snippets>
</snippetsTree>
